ImageneBio Inc

NASDAQ:IMA

Biotechnology

Healthcare
$4.61 +6.06%

+$0.35 today

Market cap
$52.00M
Beta
0.72
P/E (TTM)
-1.5
EPS (TTM)
-$4.02
52W Low $3.94High $18.00

Volume 0.00M

Average 0.35M

IMA EPS (Basic)

Net income attributable to common shareholders divided by the weighted average basic shares outstanding.

ImageneBio IncNASDAQ: IMA

EPS (Basic) · Q1 FY2026 · quarter ended Mar 2026

EPS (Basic) remains negative

Q1 FY2026 EPS (Basic) was -$0.95, compared with -$0.18 a year earlier. Trailing-twelve-month EPS (Basic) was -$4.64.

Context

  • EPS (Basic) grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EPS (Basic) reaches the consensus estimate from 3 analysts of -$3.22 (+70.1%) for the fiscal year ending Dec 2026, a step up from the -954.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$0.95-53.2% QoQ
Last fiscal yearDec 2025
-$10.76-954.9% YoY
LTMMar 2026
-$4.64-439.2% YoY
EPS (Basic) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-427.8%-1680.1%-1252.3 pp
1 year-954.9%+70.1%+1025.0 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EPS (Basic) history

USD · from the income statement

Latest · FY2025
(10.76) USD
Year-over-year change
-954.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EPS (Basic) vs competitors

How IMA compares with its peers on the latest reported figures

  • Peers report in different currencies, so EPS (Basic) is compared through growth and rates rather than absolute size.
  • Its year-over-year change of -439.2% is the 8th highest of 9, against a peer median of -5.1%.
IMA Competitors
EPS (Basic) for IMA and competitors
Company Period LTM YoY 3-year CAGR
OVIDOvid Therapeutics Inc.LTM Mar 2026-$0.35 USD+1.2%—
CNTXContext Therapeutics Inc.LTM Mar 2026-$0.42 USD-15.1%—
IFRXInflaRx N.V.LTM Mar 2026-€0.61 EUR+18.5%—
STTKShattuck Labs, Inc.LTM Mar 2026-$0.63 USD+54.7%—
CNTBConnect Biopharma Holdings LimitedFY2025-$1 USD-257.1%—
KLRSKalaris Therapeutics IncLTM Mar 2026-$2.15 USD+85.6%—
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026-$3.55 USD-11.3%—
IMAImageneBio IncLTM Mar 2026-$4.64 USD-439.2%—
STROSutro Biopharma, Inc.LTM Mar 2026-$307.72 USD-936.1%—
Peer median (excluding IMA) —-5.1%—

Competitors are the stored peer set for IMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue30.99M15.62M9.16M3.5M800K
Cost of Revenue47.11M64.32M1.02M1.53M1.03M
Gross Profit(16.12M)(48.7M)8.14M3.5M(233K)
Gross Margin-52.0%-311.8%88.9%100.0%-29.1%
Research & Development47.11M64.32M59.65M32.11M28.53M
Selling, General & Admin18.02M22.2M24.93M8.39M20.73M
Operating Expenses18.02M22.2M83.56M40.5M48.22M
Depreciation & Amortization544K751K1.02M1.53M1.03M
EBITDA(33.57M)(68.01M)(67.31M)(35.03M)(44.67M)
EBITDA Margin-108.3%-435.5%-734.8%-1000.8%-5583.3%
Operating Income(34.14M)(70.9M)(75.42M)(37M)(48.45M)
Operating Margin-110.2%-454.0%-823.3%-1057.1%-6056.4%
Interest Income23K2.15M7.11M7.37M2.04M
Interest Expense00000
Other Income / Expenses23K2.14M7.09M445K2.75M
Income Before Tax(34.12M)(68.77M)(68.33M)(36.56M)(45.7M)
Pre-Tax Margin-110.1%-440.3%-745.9%-1044.4%-5712.4%
Income Tax Expense00(162K)13K(350K)
Net Income(34.12M)(68.77M)(68.17M)(36.57M)(45.35M)
Net Margin-110.1%-440.3%-744.2%-1044.8%-5668.6%
EPS (Basic)(0.95)(1.90)(1.63)(1.02)(10.76)
EPS (Diluted)(0.95)(1.90)(1.63)(1.02)(10.76)
Weighted Avg Shares35.98M36.19M41.74M48.26M4.87M
Weighted Avg Shares (Diluted)35.98M36.19M41.74M48.26M4.87M

ImageneBio Inc

NASDAQ:IMA

Intrinsic Alpha fair value

Locked

Current Price

$4.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.